|
1
|
West AP, Koblansky AA and Ghosh S:
Recognition and signaling by toll-like receptors. Annu Rev Cell Dev
Biol. 22:409–437. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
O'Neill LA, Bryant CE and Doyle SL:
Therapeutic targeting of Toll-like receptors for infectious and
inflammatory diseases and cancer. Pharmacol Rev. 61:177–197. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fairweather D and Frisanchokiss S: Mast
cells and inflammatory heart disease: Potential drug targets.
Cardiovasc Hematol Disord Drug Targets. 8:80–90. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
de Laat MA, Gruntmeir KJ, Pollitt CC,
Mcgowan CM, Sillence MN and Lacombe VA: Hyperinsulinemia
down-regulates TLR4 expression in the mammalian heart. Front
Endocrinol (Lausanne). 5:1202014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gay NJ, Symmons MF, Monique G and Bryant
CE: Assembly and localization of Toll-like receptor signalling
complexes. Nat Rev Immunol. 14:546–558. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li H, Huang LF, Wen C, Yang ZC and Chen
CY: Roles of cardiac mast cells and Toll-like receptor 4 in viral
myocarditis among mice. Zhongguo Dang Dai Er Ke Za Zhi. 15:896–902.
2013.(In Chinese). PubMed/NCBI
|
|
7
|
Yang Y, Lv J, Jiang S, Ma Z, Wang D, Hu W,
Deng C, Fan C, Di S, Sun Y and Yi W: The emerging role of Toll-like
receptor 4 in myocardial inflammation. Cell Death Dis. 7:e22342016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sternberg EM: Neural regulation of innate
immunity: A coordinated nonspecific host response to pathogens. Nat
Rev Immunol. 6:318–328. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Beutler B, Du X and Poltorak A:
Identification of Toll-like receptor 4 (Tlr4) as the sole conduit
for LPS signal transduction: Genetic and evolutionary studies. J
Endotoxin Res. 7:277–280. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tan Y and Kagan JC: A cross-disciplinary
perspective on the innate immune responses to bacterial
lipopolysaccharide. Mol Cell. 54:212–223. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Husebye H, Halaas Ø, Stenmark H, Tunheim
G, Sandanger Ø, Bogen B, Brech A, Latz E and Espevik T: Endocytic
pathways regulate Toll-like receptor 4 signaling and link innate
and adaptive immunity. EMBO J. 25:683–692. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kagan JC, Su T, Horng T, Chow A, Akira S
and Medzhitov R: TRAM couples endocytosis of Toll-like receptor 4
to the induction of interferon-beta. Nat Immunol. 9:361–368. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu YC, Yeh W and Ohashi PS: LPS/TLR4
signal transduction pathway. Cytokine. 42:145–151. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Annane D, Bellissant E and Cavaillon JM:
Septic shock. Lancet. 365:63–78. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hotchkiss RS and Karl IE: The
Pathophysiology and Treatment of Sepsis. N Engl J Med. 348:138–150.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kaplon H and Reichert JM: Antibodies to
watch in 2019. MAbs. 11:219–238. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park J and Rikihisa Y: Inhibition of
ehrlichia risticii infection in murine peritoneal macrophages by
gamma interferon, a calcium ionophore, and concanavalin A. Infect
Immun. 59:3418–3423. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiao Y, Zhao P, Zhu J, Grabinski T, Feng
Z, Guan X, Skinner RS, Gross MD, Hay RV, Tachibana H and Cao B:
Construction of human naïve Fab library and characterization of
anti-met Fab fragment generated from the library. Mol Biotechnol.
31:41–54. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cai B, Wang M, Zhu X, Xu J, Zheng W, Zhang
Y, Zheng F, Feng Z and Zhu J: The Fab fragment of a humanized
anti-Toll like receptor 4 (TLR4) monoclonal antibody reduces the
lipopolysaccharide response via TLR4 in mouse macrophage. Int J Mol
Sci. 16:25502–25515. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hubbard WJ, Choudhry M, Schwacha MG, Kerby
JD, Rue LW III, Bland KI and Chaudry IH: Cecal ligation and
puncture. Shock. 24 (Suppl 1):S52–S57. 2005. View Article : Google Scholar
|
|
22
|
Bryant CE, Spring DR, Gangloff M and Gay
NJ: The molecular basis of the host response to lipopolysaccharide.
Nat Rev Microbiol. 8:8–14. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miller SI, Ernst RK and Bader MW: LPS,
TLR4 and infectious disease diversity. Nat Rev Microbiol. 3:36–46.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rosadini CV and Kagan JC: Early innate
immune responses to bacterial LPS. Curr Opin Immunol. 44:14–19.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lauren A, Brown AG, Samuel P and Elovitz
MA: Lipopolysaccharide induces cytokine production and decreases
extravillous trophoblast invasion through a mitogen-activated
protein kinase-mediated pathway: Possible mechanisms of first
trimester placental dysfunction. Hum Reprod. 27:61–72. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Davis MM: A prescription for human
immunology. Immunity. 29:835–838. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hayday AC and Peakman M: The habitual,
diverse and surmountable obstacles to human immunology research.
Nat Immunol. 9:575–580. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Woodcock J and Woosley R: The FDA critical
path initiative and its influence on new drug development. Annu Rev
Med. 59:1–12. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Seok J, Warren HS, Cuenca AG, Mindrinos
MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy
L, et al: Genomic responses in mouse models poorly mimic human
inflammatory diseases. Proc Natl Acad Sci USA. 110:3507–3512. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mitka M: Drug for severe sepsis is
withdrawn from market, fails to reduce mortality. JAMA.
306:2439–2440. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mestas J and Hughes CC: Of mice and not
men: Differences between mouse and human immunology. J Immunol.
172:2731–2738. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Warren HS, Fitting C, Hoff E, Adib-Conquy
M, Beasley-Topliffe L, Tesini B, Liang X, Valentine C, Hellman J,
Hayden D and Cavaillon JM: Resilience to bacterial infection:
Difference between species could be due to proteins in serum. J
Infect Dis. 201:223–232. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu Y, Chen S, Cao Y, Zhou P, Chen Z and
Cheng K: Discovery of novel small molecule TLR4 inhibitors as
potent anti-inflammatory agents. Eur J Med Chem. 154:253–266. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Andresen L, Theodorou K, Grünewald S,
Czech-Zechmeister B, Könnecke B, Lühder F and Trendelenburg G:
Evaluation of the therapeutic potential of Anti-TLR4-antibody
MTS510 in experimental stroke and significance of different routes
of application. PLoS One. 11:e1484282016. View Article : Google Scholar
|
|
35
|
Neal MD, Jia H, Eyer B, Good M, Guerriero
CJ, Sodhi CP, Afrazi A, Prindle T Jr, Ma C, Branca M, et al:
Discovery and validation of a new class of small molecule Toll-like
receptor 4 (TLR4) inhibitors. PLoS One. 8:e657792013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ohta S, Bahrun U, Shimazu R, Matsushita H,
Fukudome K and Kimoto M: Induction of long-term lipopolysaccharide
tolerance by an agonistic monoclonal antibody to the toll-like
receptor 4/MD-2 complex. Clin Vaccine Immunol. 13:1131–1136. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Akashi-Takamura S, Furuta T, Takahashi K,
Tanimura N, Tanimura N, Kusumoto Y, Kobayashi T, Saitoh S, Adachi
Y, Doi T and Miyake K: Agonistic antibody to TLR4/MD-2 protects
mice from acute lethal hepatitis induced by TNF-alpha. J Immunol.
176:4244–4251. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang M, Zheng W, Zhu X, Xu J, Cai B, Zhang
Y, Zheng F, Zhou L, Yang Z, Zhang X, et al: A human anti-Toll like
receptor 4 Fab fragment inhibits lipopolysaccharide-induced
pro-inflammatory cytokines production in macrophages. PLoS One.
11:e1468562016.
|
|
39
|
Park BS, Song DH, Kim HM, Choi BS, Lee H
and Lee JO: The structural basis of lipopolysaccharide recognition
by the TLR4-MD-2 complex. Nature. 458:1191–1195. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Eckert JK, Kim YJ, Kim JI, Gürtler K, Oh
DY, Sur S, Lundvall L, Hamann L, van der Ploeg A, Pickkers P, et
al: The crystal structure of lipopolysaccharide binding protein
reveals the location of a frequent mutation that impairs innate
immunity. Immunity. 39:647–660. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim JI, Lee CJ, Jin MS, Lee CH, Paik SG,
Lee H and Lee JO: Crystal structure of CD14 and its implications
for lipopolysaccharide signaling. J Biol Chem. 280:11347–11351.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kim SJ and Kim HM: Dynamic
lipopolysaccharide transfer cascade to TLR4/MD2 complex via LBP and
CD14. BMB Rep. 50:55–57. 2017. View Article : Google Scholar : PubMed/NCBI
|
